➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Dow
AstraZeneca
Mallinckrodt
Merck

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Patent: 7,629,311

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,629,311
Title:Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
Abstract: A method for delivering a biologic to a human with Alzheimer\'s-related dementia, comprising administering the biologic parenterally into the perispinal space of the human without direct intrathecal injection, and thereafter positioning the human\'s head below the horizontal. The method further includes delivering a TNF antagonist to the brain of a human for treating mild cognitive impairment, Alzheimer\'s related dementia, or vascular dementia, comprising administering the TNF antagonist golimumab parenterally into the perispinal space of the human without direct intrathecal injection, and thereafter positioning the human in a Trendelenburg position, for delivery of the golimumab to the brain via the human\'s vertebral venous system.
Inventor(s): Tobinick; Edward Lewis (Los Angeles, CA)
Assignee: Tobinick; Edward Lewis (Los Angeles, CA)
Application Number:11/601,799
Patent Claims:see list of patent claims

Details for Patent 7,629,311

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Tobinick; Edward Lewis (Los Angeles, CA) 2019-02-24 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial Tobinick; Edward Lewis (Los Angeles, CA) 2019-02-24 RX Orphan search
Octapharma Usa Inc OCTAGAM IMMUNE GLOBULIN (HUMAN) immune globulin SOLUTION 125062 1 2004-05-21   Start Trial Tobinick; Edward Lewis (Los Angeles, CA) 2019-02-24 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Moodys
Merck
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.